Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 21;6(6):e010676.
doi: 10.1136/bmjopen-2015-010676.

Tranexamic acid in hip fracture patients: a protocol for a randomised, placebo controlled trial on the efficacy of tranexamic acid in reducing blood loss in hip fracture patients

Elizabeth Bishop Gausden  1 , Matthew R Garner  2 , Stephen J Warner  1 , Ashley Levack  1 , Andrew M Nellestein  3 , Tiffany Tedore  4 , Eva Flores  5 , Dean G Lorich  3
Affiliations

Tranexamic acid in hip fracture patients: a protocol for a randomised, placebo controlled trial on the efficacy of tranexamic acid in reducing blood loss in hip fracture patients

Elizabeth Bishop Gausden et al. BMJ Open. .

Abstract

Introduction: There is a high incidence of blood transfusion following hip fractures in elderly patients. Tranexamic acid (TXA) has proven efficacy in decreasing blood loss in general trauma patients as well as patients undergoing elective orthopaedic surgery. A randomised controlled trial will measure the effect of TXA in a population of patients undergoing hip fracture surgery.

Methods: This is a double-blinded, randomised placebo-controlled trial. Patients admitted through the emergency room that are diagnosed with an intertrochanteric or femoral neck fracture will be eligible for enrolment and randomised to either treatment with 1 g of intravenous TXA or intravenous saline at the time of skin incision. Patients undergoing percutaneous intervention for non-displaced or minimally displaced femoral neck fractures will not be eligible for enrolment. Postoperative transfusion rates will be recorded and blood loss will be calculated from serial haematocrits.

Ethics and dissemination: This protocol was approved by the Institutional Review Board (IRB) and is registered with clinicaltrials.gov. The findings of the trial will be disseminated through peer-reviewed journals and conference presentations.

Trial registration number: NCT01940536.

Keywords: blood transfusion; hip fracture; tranexamic acid.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study Design (TXA: tranexamic acid; PRBC: packed red blood cells).
See this image and copyright information in PMC

References

    1. Brauer CA, Coca-Perraillon M, Cutler DM et al. . Incidence and mortality of hip fractures in the United States. JAMA 2009;302:1573–9. 10.1001/jama.2009.1462 - DOI - PMC - PubMed
    1. Richmond J, Aharonoff GB, Zuckerman JD et al. . Mortality risk after hip fracture. J Orthop Trauma 2003;17:53–6. 10.1097/00005131-200301000-00008 - DOI - PubMed
    1. Heyes GJ, Tucker A, Marley D et al. . Predictors for 1-year mortality following hip fracture: a retrospective review of 465 consecutive patients. Eur J Trauma Emerg Surg 2015. [Epub ahead of print Aug 2015]. 10.1007/s00068-015-0556-2 - DOI - PubMed
    1. Shah MR, Aharonoff GB, Wolinsky P et al. . Outcome after hip fracture in individuals ninety years of age and older. J Orthop Trauma 2001;15:34–9. 10.1097/00005131-200101000-00007 - DOI - PubMed
    1. Sathiyakumar V, Greenberg SE, Molina CS et al. . Hip fractures are risky business: an analysis of the NSQIP data. Injury 2015;46:703–8. 10.1016/j.injury.2014.10.051 - DOI - PubMed

Publication types

MeSH terms

Associated data